title: The impact of inherited thrombophilia on first trimester combined aneuploidy screening test parameters.
abstract: OBJECTIVE
  To determine whether inherited thrombophilia affects components of first trimester combined aneuploidy screening test.
  
  
  METHODS
  A case-control study was performed between January 1st and December 31st 2011, at a tertiary referral hospital. Singleton pregnancies with inherited thrombophilia that underwent first trimester (11-13(+6) week) combined aneuploidy screening test were included in the study. Pregnancy associated plasma protein-A (PAPP-A), free beta-human chorionic gonadotropin (fbHCG) and fetal nuchal translucency (NT) were compared between the study group and controls.
  
  
  RESULTS
  Within the study period, 15,881 women with singleton pregnancies had a combined first trimester aneuploidy screening test at our institution. Among these, 207 women met the inclusion criteria. A control group that comprised 625 women with similar gestational age was generated, using a 1:3 ratio. PAPP-A levels were significantly higher, whereas fbHCG levels and fetal NT measurements were lower in women with inherited thrombophilia (p < 0.001).
  
  
  CONCLUSIONS
  Our study suggested that PAPP-A, free b-HCG and NT MoM levels display alterations in women with inherited thrombophilia. Future trials are needed to assess the need for readjustment of risk in these patients.
authors.affiliation: Department of Obstetrics and Gynecology, Zekai Tahir Burak Women's Health Education and Research Hospital , Ankara , Turkey.
authors.forename: Mehmet Fatih
authors.initials: MF
authors.lastname: Karsli
authors.forename: Eralp
authors.initials: E
authors.lastname: Baser
authors.forename: Kerem Doga
authors.initials: KD
authors.lastname: Seckin
authors.forename: Mahmut İlkin
authors.initials: Mİ
authors.lastname: Yeral
authors.forename: Cihan
authors.initials: C
authors.lastname: Togrul
authors.forename: Mustafa
authors.initials: M
authors.lastname: Ugur
mesh_terms: D000293:Adolescent; D000328:Adult; D000782:Aneuploidy; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D062145:Maternal Serum Screening Tests; D048208:Nuchal Translucency Measurement; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy; D011261:Pregnancy Trimester, First; D011266:Pregnancy-Associated Plasma Protein-A / Q000378:metabolism*; D011296:Prenatal Diagnosis / Q000379:methods; D018570:Risk Assessment; D019851:Thrombophilia / Q000188:drug therapy; D055815:Young Adult
chemical_list: D015415:Biomarkers; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D011266:Pregnancy-Associated Plasma Protein-A